证券代码：603301 证券简称：振德医疗 公告编号：2025-035 振德医疗用品股份有限公司 股票交易异常波动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 1、振德医疗用品股份有限公司(以下简称:"公司"、"本公司") 股票于 2025 年 9 月 30 日、10 月 9 日、10 月 10 日连续 3 个交易日内 收盘价格涨幅偏离值累计超过 20%,根据《上海证券交易所交易规则》 的有关规定,属于股票交易异常波动情形。 2、经公司自查,并书面发函询问控股股东及实际控制人,截至本 公告披露日,确认不存在应披露而未披露的重大事项或重要信息。 3、敬请广大投资者注意投资风险。 一、股票交易异常波动的具体情况 经公司自查，公司目前生产经营正常,近期外部经营环境和行业 政策没有发生重大变化。 （二）重大事项情况 公司控股股东浙江振德控股有限公司（以下简称"浙江振德"） 及其全资子公司许昌振德园林绿化工程有限公司（以下简称"许昌园 林"）于 2025 年 9 月 10 日与孙纪木、中国工商银行股份有限公司绍 ...

证券之星消息，10月9日医疗器械板块较上一交易日上涨0.83%，振德医疗领涨。当日上证指数报收于 3933.97，上涨1.32%。深证成指报收于13725.56，上涨1.47%。医疗器械板块个股涨跌见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 从资金流向上来看，当日医疗器械板块主力资金净流入6915.01万元，游资资金净流入1.81亿元，散户资 金净流出2.5亿元。医疗器械板块个股资金流向见下表： | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入(元) | | 游资净占比 散户净流入(元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 688271 联影医疗 | | 1.47 Z | 7.45% | -9608.14万 | -4.87% | -5095.56万 | -2.58% | | 603301 振德医疗 | | 8818.91万 | 21.21% | -964.82万 | -2.32% | -7854.09万 | - ...

Core Insights - The article highlights the significant net inflow of main funds into specific stocks over a period of five days or more, indicating strong investor interest and potential growth opportunities in these companies [1][2] Group 1: Key Stocks with Net Inflows - Cambrian Biologics-U (688256) leads with a continuous net inflow for 30 days, totaling 4.192 billion CNY, with a price increase of 41.87% [1] - Huayou Cobalt (603799) follows with a net inflow of 1.829 billion CNY over five days, reflecting a 25.57% increase [1] - Zhongnan Media (601098) has seen a net inflow for eight days, amounting to 1.111 billion CNY, with a minimal price change of 0.16% [2] Group 2: Notable Inflow Metrics - The highest net inflow percentage relative to trading volume is observed in Hebang Biology (603077), with a 13.89% ratio and a price increase of 8.90% over five days [1] - The total net inflow for Cambrian Biologics-U over 30 days is 4.192 billion CNY, indicating strong market confidence [1] - Other notable stocks include Tianqi Lithium (002466) with a net inflow of 576 million CNY and a price increase of 11.09% [1]

Investment Rating - The report maintains a "Strong Buy" rating for the company with a target price of 58 yuan [2][7]. Core Views - The company's H1 2025 revenue reached 2.1 billion yuan, a year-on-year increase of 2.83%, while the net profit attributable to shareholders decreased by 20.70% to 128 million yuan [2][7]. - The domestic retail business is under pressure, but overseas operations are steadily improving, with overseas revenue growing by 13% to 1.292 billion yuan in H1 2025 [2][7]. - The company is focusing on optimizing its product mix and enhancing market penetration, with its products covering nearly 9,200 hospitals across China [2][7]. Financial Performance - H1 2025 revenue breakdown: Surgical infection control revenue was 900 million yuan (+14%), basic care revenue was 430 million yuan (-23%), stoma and modern wound care revenue was 390 million yuan (+17%), and pressure treatment and fixation revenue was 230 million yuan (-4%) [2][7]. - The company expects net profits for 2025-2027 to be 400 million, 450 million, and 530 million yuan respectively, with corresponding P/E ratios of 29, 26, and 22 [3][7]. Market Position - The domestic hospital line revenue was 533 million yuan (+1%), while the retail line revenue was 214 million yuan (-37%) in H1 2025 [2][7]. - The company has implemented a "721" product focus strategy to enhance sales efficiency, achieving a 99% coverage rate in top 100 chain pharmacies across China [2][7]. Future Outlook - The report projects steady revenue growth with a forecasted total revenue of 4.264 billion yuan in 2024, increasing to 6.120 billion yuan by 2027, reflecting a compound annual growth rate of 14.7% [3][8]. - The company is actively expanding its global footprint, particularly in Southeast Asia, the Middle East, and Africa, to mitigate geopolitical risks and enhance its overseas business [2][7].

Core Viewpoint - Zhendemedical experienced a 5.44% increase in stock price, reaching 43.26 CNY per share, with a trading volume of 135 million CNY and a turnover rate of 1.20%, resulting in a total market capitalization of 11.527 billion CNY [1] Company Overview - Zhendemedical is located in Shaoxing City, Zhejiang Province, and was established on August 18, 1994. The company went public on April 12, 2018. Its main business involves the production, research, and sales of medical dressings [1] - The revenue composition of Zhendemedical includes: - Surgical infection control: 43.04% - Basic care: 20.46% - Stoma and modern wound care: 18.59% - Pressure treatment and fixation: 10.75% - Infection control protection: 6.58% - Others: 0.58% [1] Shareholder Information - Zhendemedical's top circulating shareholder is a fund under China Merchants Fund, specifically the China Merchants Core Competitiveness Mixed A (014412), which increased its holdings by 581,000 shares in the second quarter, totaling 3.4286 million shares, representing 1.29% of circulating shares. The estimated floating profit today is approximately 7.6459 million CNY [2] - The China Merchants Core Competitiveness Mixed A fund was established on April 13, 2022, with a current scale of 2.993 billion CNY. Year-to-date returns are 22.19%, ranking 4235 out of 8173 in its category; the one-year return is 47.73%, ranking 3179 out of 8003; and since inception, the return is 58.91% [2] Fund Manager Information - The fund manager of China Merchants Core Competitiveness Mixed A is Zhu Hongyu, who has a cumulative tenure of 14 years and 133 days. The total asset scale of the fund is 4.964 billion CNY, with the best fund return during his tenure being 57.72% and the worst being -12.86% [3] Fund Holdings - Another fund under China Merchants Fund, the China Merchants Social Responsibility Mixed A (018309), holds 1.367 million shares of Zhendemedical, accounting for 2.96% of the fund's net value, making it the tenth largest holding. The estimated floating profit today is approximately 3.0484 million CNY [4] - The China Merchants Social Responsibility Mixed A fund was established on April 26, 2023, with a current scale of 974 million CNY. Year-to-date returns are 29.77%, ranking 3226 out of 8173; the one-year return is 54.04%, ranking 2634 out of 8003; and since inception, the return is 10.28% [4] Fund Manager Information (Social Responsibility Fund) - The fund manager of China Merchants Social Responsibility Mixed A is also Zhu Hongyu, with the same cumulative tenure and asset scale as mentioned previously [5]

Group 1: New Stock Issuances - Cash option declaration period for *ST Tianmao (000627) is from September 15 to September 19, 2025[1] - *ST Zitian (300280) has 11 trading days remaining until the last trading day during the delisting arrangement period[1] - *ST Dongtong (300379) has reported severe abnormal fluctuations in stock price[1] Group 2: Market Alerts - Jiushi Media (601929) has experienced significant abnormal fluctuations in stock price[1] - Xian Dao Intelligent (300450) has reported severe abnormal fluctuations in stock price[1] - Hangke Technology (688006) has issued a notice regarding stock performance[1] Group 3: Trading Notifications - Shanghai Construction (600170) has issued a trading notification on September 18, 2025[1] - Junsheng Electronics (600699) has issued a trading notification on September 18, 2025[1] - ST Changyuan (600525) has issued a trading notification on September 18, 2025[1]

Investment Rating - The report maintains a "Recommended" investment rating for the pharmaceutical and biotechnology industry [6] Core Viewpoints - The pharmaceutical sector has outperformed the CSI 300 index, with the Shenwan Pharmaceutical Biotechnology Index rising by 2.46% from September 1 to September 14, 2025, and by 26.80% year-to-date, surpassing the CSI 300 index by 1.16 percentage points and 11.88 percentage points respectively [1][13] - The current valuation of the pharmaceutical sector stands at 31.58 times (TTM overall method, excluding negative values), with a premium of 148.92% compared to the CSI 300 index [16] - The National Medical Products Administration (NMPA) has announced measures to optimize the review and approval process for innovative drug clinical trials, aiming to complete reviews within 30 working days for eligible applications [20] - The ongoing reforms in drug review and approval systems are expected to enhance the efficiency of clinical trials and accelerate the development of innovative drugs, benefiting companies in this sector [21] Summary by Sections 1. Biweekly Market Review - The pharmaceutical sector's performance from September 1 to September 14, 2025, shows a 2.46% increase, ranking 8th among 31 Shenwan first-level industry indices [11] - Year-to-date, the pharmaceutical sector has increased by 26.80%, also ranking 8th among the indices [13] - The top ten stocks by increase include Zhendemedical (+46.67%), Haooubo (+34.22%), and Kangwei Century (+30.28%), while the top ten stocks by decrease include Shutaishen (-24.15%) and Shanghai Yizhong (-15.39%) [17][18] 2. Important Events - On September 12, 2025, the NMPA released an announcement to support innovative drug development by optimizing the clinical trial review process [20] 3. Industry Insights - The report emphasizes the acceleration of innovative drug development in China, with significant results emerging and ongoing policy optimizations expected to further support this trend [21] - The second half of 2025 is expected to see continued focus on innovative drugs, international expansion, and the clearing of procurement processes, with specific attention to insulin and orthopedic sectors [21]

New Stock Issuance - Cash option declaration period for *ST Tianmao (000627) is from September 15 to September 19, 2025[1] - *ST Zitian (300280) has 12 trading days remaining until the last trading day during the delisting arrangement period[1] Trading Alerts - *ST Jishi Media (601929) reported severe abnormal fluctuations in stock price[1] - *ST Yushun (002289) and *ST Weier (002058) are under scrutiny due to abnormal trading activities[1] Company Announcements - *ST Gao Hong (000851) and *ST Dongtong (300379) have recent announcements regarding their financial status[1] - Shanghai Construction (600170) and Zhongke Shuguang (603019) have disclosed important updates on their operations[1] Market Trends - The report indicates a trend of increased scrutiny on companies with abnormal trading patterns, reflecting a tightening regulatory environment[2] - The number of companies under cash option declarations and delisting arrangements suggests a potential increase in market volatility[1]

New Stock Issuance - Jin Hua New Material (920015) issued at a price of 18.15[1] - Jianfa Zhixin (301584) issued at a price of 7.05[1] Market Alerts - Cash option declaration period for *ST Tianmao (000627) from September 15 to September 19, 2025[1] - 13 trading days remaining for the delisting period of Zitian Tui (300280)[1] - Severe abnormal fluctuation reported for Jishi Media (601929)[1] Other Announcements - Multiple companies including Shanghai Construction (600170) and Zhongke Shuguang (603019) have recent announcements linked[1] - Various stocks are under scrutiny for abnormal trading activities, including *ST Yu Shun (002289) and ST Huaneng (000851)[3]

Core Viewpoint - The stock of Zhend Medical Supplies Co., Ltd. experienced an abnormal trading fluctuation, with a cumulative closing price increase exceeding 20% over three consecutive trading days from September 11 to September 15, 2025 [2][4]. Group 1: Stock Trading Abnormality - The stock price deviation was identified as an abnormal trading situation according to the Shanghai Stock Exchange trading rules [2][4]. - The company confirmed that there were no undisclosed significant matters or important information as of the announcement date [2][6]. Group 2: Company Operations - The company reported that its production and operations are normal, with no significant changes in the external operating environment or industry policies [5]. Group 3: Major Transactions - On September 10, 2025, the controlling shareholder, Zhejiang Zhend Holdings Co., Ltd., and its wholly-owned subsidiary signed a share transfer agreement to transfer a total of 13,322,560 shares (5.00% of total share capital) at a price of RMB 26.74 per share [6]. - The total transaction value is approximately RMB 356.25 million [6]. Group 4: Compliance and Risk - The share transfer is subject to compliance review by the Shanghai Stock Exchange and must complete the share transfer registration process, which may involve the release of pledged shares [7]. - The company has not identified any media reports or market rumors that could significantly impact the stock price [8]. - There were no significant stock trading activities by directors, senior management, or controlling shareholders during the abnormal trading period [9].